SE442201B - 2-/3-/4-(3-kloro-4-fluoro-fenyl-1-piperazinyl/arpayl/-1,2,4-triazolo/4,3-a/pyridin-3(2h)-on, forfarande for framstellning derav och komposition derav - Google Patents
2-/3-/4-(3-kloro-4-fluoro-fenyl-1-piperazinyl/arpayl/-1,2,4-triazolo/4,3-a/pyridin-3(2h)-on, forfarande for framstellning derav och komposition deravInfo
- Publication number
- SE442201B SE442201B SE8102093A SE8102093A SE442201B SE 442201 B SE442201 B SE 442201B SE 8102093 A SE8102093 A SE 8102093A SE 8102093 A SE8102093 A SE 8102093A SE 442201 B SE442201 B SE 442201B
- Authority
- SE
- Sweden
- Prior art keywords
- chloro
- triazolo
- pharmaceutically acceptable
- piperazinyl
- pyridin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 10
- GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 title claims description 8
- -1 3-CHLORO-4-FLUORO-PHENYL-1-PIPERAZINYL Chemical class 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000000202 analgesic effect Effects 0.000 claims description 7
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000000506 psychotropic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000007859 condensation product Substances 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 9
- 229960003991 trazodone Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241001279009 Strychnos toxifera Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960005152 pentetrazol Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 229960005453 strychnine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000252095 Congridae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100036988 Cyclin-dependent kinase 2-interacting protein Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 101000737869 Homo sapiens Cyclin-dependent kinase 2-interacting protein Proteins 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940080861 demerol Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21246/80A IT1147349B (it) | 1980-04-09 | 1980-04-09 | 2-parentesi quadra aperta 3-parentesi quadra aperta 4-(3-cloro-4-fluorofenil)-1-piperfrazinil parentesi quadra propil parentesi quadra chiusa-1,2,4-triazolo parentesi quadra aperta 4,3 parentesi quadra chiusa piridin-3(2h)-one |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8102093L SE8102093L (sv) | 1981-10-10 |
| SE442201B true SE442201B (sv) | 1985-12-09 |
Family
ID=11178966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8102093A SE442201B (sv) | 1980-04-09 | 1981-04-01 | 2-/3-/4-(3-kloro-4-fluoro-fenyl-1-piperazinyl/arpayl/-1,2,4-triazolo/4,3-a/pyridin-3(2h)-on, forfarande for framstellning derav och komposition derav |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2269608A1 (en) | 1996-11-12 | 1998-05-22 | Sepracor Inc. | 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole |
| AU5178998A (en) * | 1996-11-12 | 1998-06-03 | Sepracor, Inc. | 2(r),4(s),(r),(s)- and 2(s),4(r),(r),(s)-hydroxyitraconazole- and hydroxysaperconazole derivatives |
| US6147077A (en) * | 1999-04-29 | 2000-11-14 | Sepracor Inc. | 2R,4S-hydroxyitraconazole isomers |
| US8686158B2 (en) * | 2008-06-05 | 2014-04-01 | President And Fellows Of Harvard College | High-valent palladium fluoride complexes and uses thereof |
| CA2742869A1 (en) | 2008-11-20 | 2010-05-27 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| JP2012514655A (ja) * | 2009-01-09 | 2012-06-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | フッ素含有化合物およびその使用法 |
| US9150516B2 (en) | 2011-04-12 | 2015-10-06 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| US9273083B2 (en) | 2012-09-26 | 2016-03-01 | President And Fellows Of Harvard College | Nickel fluorinating complexes and uses thereof |
| WO2015058047A2 (en) | 2013-10-18 | 2015-04-23 | President And Fellows Of Harvard College | Fluorination of organic compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1066857B (it) * | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
| FR8135M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1968-12-31 | 1970-08-10 | ||
| US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| UST100505I4 (en) | 1980-03-17 | 1981-04-07 | Triazolo[4,3-a]pyridin-3(2H)-ones |
-
1980
- 1980-04-09 IT IT21246/80A patent/IT1147349B/it active
-
1981
- 1981-02-10 IL IL62101A patent/IL62101A/xx unknown
- 1981-02-12 US US06/234,065 patent/US4402956A/en not_active Expired - Fee Related
- 1981-02-17 BE BE0/203815A patent/BE887547A/fr not_active IP Right Cessation
- 1981-02-25 CH CH1240/81A patent/CH652397A5/it not_active IP Right Cessation
- 1981-03-02 NL NL8100998A patent/NL8100998A/nl not_active Application Discontinuation
- 1981-03-16 GB GB8108158A patent/GB2073747B/en not_active Expired
- 1981-03-30 CA CA000374133A patent/CA1176253A/en not_active Expired
- 1981-03-30 YU YU00831/81A patent/YU83181A/xx unknown
- 1981-04-01 DE DE19813112984 patent/DE3112984A1/de not_active Withdrawn
- 1981-04-01 SE SE8102093A patent/SE442201B/sv not_active IP Right Cessation
- 1981-04-01 FI FI811000A patent/FI69306C/fi not_active IP Right Cessation
- 1981-04-02 AU AU69043/81A patent/AU529605B2/en not_active Ceased
- 1981-04-07 KR KR1019810001166A patent/KR840002292B1/ko not_active Expired
- 1981-04-07 AR AR284885A patent/AR225076A1/es active
- 1981-04-07 PT PT72813A patent/PT72813B/pt unknown
- 1981-04-07 FR FR8106952A patent/FR2480285A1/fr active Granted
- 1981-04-07 GR GR64614A patent/GR73620B/el unknown
- 1981-04-08 ES ES501188A patent/ES501188A0/es active Granted
- 1981-04-09 AT AT0165081A patent/AT377262B/de not_active IP Right Cessation
- 1981-04-09 JP JP5420581A patent/JPS56158784A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2480285A1 (fr) | 1981-10-16 |
| CH652397A5 (it) | 1985-11-15 |
| GB2073747B (en) | 1983-09-07 |
| CA1176253A (en) | 1984-10-16 |
| PT72813A (en) | 1981-05-01 |
| FR2480285B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-02-24 |
| FI811000L (fi) | 1981-10-10 |
| FI69306C (fi) | 1986-01-10 |
| AR225076A1 (es) | 1982-02-15 |
| NL8100998A (nl) | 1981-11-02 |
| JPS56158784A (en) | 1981-12-07 |
| ES8202817A1 (es) | 1982-02-01 |
| KR840002292B1 (ko) | 1984-12-15 |
| GB2073747A (en) | 1981-10-21 |
| ATA165081A (de) | 1984-07-15 |
| US4402956A (en) | 1983-09-06 |
| IL62101A0 (en) | 1981-03-31 |
| FI69306B (fi) | 1985-09-30 |
| KR830005218A (ko) | 1983-08-03 |
| YU83181A (en) | 1983-12-31 |
| AU6904381A (en) | 1981-10-15 |
| GR73620B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-03-26 |
| BE887547A (fr) | 1981-06-15 |
| SE8102093L (sv) | 1981-10-10 |
| AT377262B (de) | 1985-02-25 |
| IT1147349B (it) | 1986-11-19 |
| DE3112984A1 (de) | 1981-12-24 |
| IT8021246A0 (it) | 1980-04-09 |
| IL62101A (en) | 1984-01-31 |
| PT72813B (en) | 1982-04-02 |
| ES501188A0 (es) | 1982-02-01 |
| AU529605B2 (en) | 1983-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10004701B2 (en) | Methods and compositions for treating infection | |
| JP6772272B2 (ja) | シクロヘキサン誘導体、又はその立体異性体、又はその塩及びその調製と応用 | |
| MX2010012186A (es) | Antagonistas del receptor nmda para el tratamiento de transtornos neuropsiquitricos. | |
| ES2929140T3 (es) | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat | |
| US20120046246A1 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
| FR2513250A1 (fr) | Nouvelles cyclobutene-3,4-diones substituees | |
| US20100197666A1 (en) | (thio) -carbamoyl-cyclohexane derivatives and method for treating schizophrenia | |
| JP2017538676A (ja) | ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤 | |
| AU2006301708A1 (en) | Glycyrrhetinic acid-30-amide derivatives and the uses thereof | |
| CA3166938A1 (en) | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | |
| SE442201B (sv) | 2-/3-/4-(3-kloro-4-fluoro-fenyl-1-piperazinyl/arpayl/-1,2,4-triazolo/4,3-a/pyridin-3(2h)-on, forfarande for framstellning derav och komposition derav | |
| JP2016185947A (ja) | ＩＲＥ−１αインヒビター | |
| RU2021269C1 (ru) | Пиридил- или пиримидилсодержащие производные пиперазина или 1,4-диазациклогептана или их фармакологически активные кислотно-аддитивные соли, обладающие психотропным действием | |
| KR20030053475A (ko) | 5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물 | |
| WO2023081897A1 (en) | Isotopically enriched 3,4-methylenedioxy-n-ethylamphetamine (mde) and stereoisomers thereof | |
| CA3213395A1 (en) | Compositions and methods for treating polycythemia | |
| JP2021512138A (ja) | ２−（αヒドロキシペンチル）安息香酸の有機アミンエステル誘導体薬物 | |
| KR101455484B1 (ko) | 항말라리아제로서 피페라진 | |
| CN116854663B (zh) | 阿朴菲类生物碱衍生物及其制备方法和应用 | |
| WO2013070107A1 (ru) | ПРОИЗВОДНЫЕ 5Н-ДИБЕНЗО[b,е] [1,4]ДИАЗЕПИНA И ИХ ПРИМЕНЕНИЕ | |
| US20240325382A1 (en) | Compositions and methods for treating anemia associated with a ribosomal disorder | |
| TW200306189A (en) | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | |
| US9932302B1 (en) | N-phenyl and N-benzyl enaminones and methods for using same | |
| RU2008149076A (ru) | Действующее вещество для лечения алкогольной зависимости, фармацевтическая композиция, лекарственное средство, способ получения фармацевтической композиции и лекарственного средства и способ лечения | |
| CA3037928A1 (en) | Combinatory treatment strategies of cancer based on rna polymerase i inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8102093-5 Effective date: 19880822 Format of ref document f/p: F |